Status: Not yet recruiting
A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Participants needed: 76
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Kivu Bioscience Inc.Updated: Apr 22, 2026Locations: 1
Eligibility criteria
Male or female ≥18 years of age [+5]
Prior treatment with any ADC with a topoisomerase 1 inhibitor payload [+5]